<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03111901</url>
  </required_header>
  <id_info>
    <org_study_id>18537</org_study_id>
    <nct_id>NCT03111901</nct_id>
  </id_info>
  <brief_title>Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer</brief_title>
  <acronym>UVA-AM-002</acronym>
  <official_title>Low-dose Interleukin-2 and Pembrolizumab Among Patients With Metastatic Melanoma and Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>William Grosh, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and disease control rate of the combination of&#xD;
      pembrolizumab plus low-dose interleukin-2 in patients who have either advanced melanoma or&#xD;
      renal cell cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    funding was withdrawn&#xD;
  </why_stopped>
  <start_date type="Actual">October 29, 2018</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: adverse event profile</measure>
    <time_frame>up to 90 days post-treatment</time_frame>
    <description>Obtain preliminary data on the safety of LD-IL2 with pembrolizumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease control rate: melanoma</measure>
    <time_frame>baseline and every 9 weeks (up to week 104)</time_frame>
    <description>Estimate the disease control rate (CR+PR+SD by RECIST 1.1) among candidate patients with metastatic melanoma treated with pembrolizumab and LD-IL2 and to determine whether disease control is significantly improved. SD for 6 months or more will be considered SD for the purpose of this assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease control rate: renal cell cancer</measure>
    <time_frame>baseline and every 9 weeks (up to week 104)</time_frame>
    <description>Estimate the disease control rate (CR+PR+SD by RECIST 1.1) among patients with metastatic renal cell cancer treated with pembrolizumab and LD-IL2 and to determine whether disease control is significantly improved. SD for 6 months or more will be considered SD for the purpose of this assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival: metastatic melanoma</measure>
    <time_frame>From first response (SD/PR/CR) to time of recurrence/progression or death from any cause, whichever occurs first, assessed for an estimated total of 120 months.</time_frame>
    <description>Estimate progression-free survival defined as the duration of time from first response (SD/PR/CR) to time of recurrence/progression or death from any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival: renal cell cancer</measure>
    <time_frame>From first response (SD/PR/CR) to time of recurrence/progression or death from any cause, whichever occurs first, assessed for an estimated total of 120 months.</time_frame>
    <description>Estimate progression-free survival defined as the duration of time from first response (SD/PR/CR) to time of recurrence/progression or death from any cause, whichever occurs first</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Carcinoma, Renal Cell</condition>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab (200 mg) administered intravenously (day 2 of cycle 1; day 1 of cycles 2 and beyond); Low dose-interleukin 2 (LD-IL2) 12 MIU/m2 administered subcutaneously (days 1-5 and 8-12 of each cycle); each cycle is 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Level -1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab (200 mg) administered intravenously (day 2 of cycle 1; day 1 of cycles 2 and beyond); Low dose-interleukin 2 (LD-IL2) 5 MIU/m2 administered subcutaneously (days 1-5 and 8-12 of each cycle); each cycle is 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab solution</description>
    <arm_group_label>Level -1</arm_group_label>
    <arm_group_label>Level 1</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>KEYTRUDA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-2</intervention_name>
    <description>Interleukin-2 solution</description>
    <arm_group_label>Level -1</arm_group_label>
    <arm_group_label>Level 1</arm_group_label>
    <other_name>IL-2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria&#xD;
&#xD;
          -  Stage IV or unresectable stage III malignant melanoma or renal cell carcinoma.&#xD;
&#xD;
          -  Melanoma&#xD;
&#xD;
               -  Patients must have failed anti-PD-1/PD-L1 antibody therapy.&#xD;
&#xD;
               -  Patients must have failed ipilimumab or be intolerant of ipilimumab and therefore&#xD;
                  unable to receive ipilimumab.&#xD;
&#xD;
               -  Patients may, but are not obligated, to have failed high- dose IL2.&#xD;
&#xD;
               -  BRAF status must be known or unable to be performed. If the melanoma expresses a&#xD;
                  BRAF mutation of V600E, V600K, or V600R patient must have received and progressed&#xD;
                  through a BRAF inhibitor or have failed that therapy due to toxicity.&#xD;
&#xD;
          -  Renal Cell Carcinoma&#xD;
&#xD;
               -  Patients must have failed anti-PD-1/PD-L1 antibody therapy.&#xD;
&#xD;
               -  Patients must have failed a VEGF pathway inhibitor and a second tyrosine kinase&#xD;
                  inhibitor.&#xD;
&#xD;
               -  Patients may, but are not obligated, to have failed high- dose IL2.&#xD;
&#xD;
          -  Measurable disease based upon RECIST 1.1.&#xD;
&#xD;
          -  Subjects with brain metastases will be eligible if the following are true:&#xD;
&#xD;
          -  Subjects with ≤ 3 brain metastases&#xD;
&#xD;
               -  All metastases are ≤ 3 cm&#xD;
&#xD;
               -  All metastases have been treated and are asymptomatic&#xD;
&#xD;
               -  Steroids are not required for management of the brain metastases&#xD;
&#xD;
               -  All metastases have been stable for 1 month following treatment&#xD;
&#xD;
          -  Subjects with &gt; 3 brain metastases&#xD;
&#xD;
               -  All metastases are ≤ 3 cm&#xD;
&#xD;
               -  All metastases have been treated and are asymptomatic&#xD;
&#xD;
               -  Steroids are not required for management of the brain metastases&#xD;
&#xD;
               -  All metastases have been stable for 6 months following treatment&#xD;
&#xD;
          -  Performance status: ECOG 0-1.&#xD;
&#xD;
          -  Adequate organ function.&#xD;
&#xD;
          -  Ability to provide informed consent.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Currently participating and receiving study therapy or has participated in a study of&#xD;
             an investigational agent and received study therapy or used an investigational device&#xD;
             within 4 weeks of the first dose of treatment.&#xD;
&#xD;
          -  Has a diagnosis of primary or secondary immunodeficiency or is receiving systemic&#xD;
             steroid therapy or any other form of immunosuppressive therapy within 3 weeks prior to&#xD;
             the first dose of trial treatment. Replacement doses of steroids are permitted.&#xD;
&#xD;
          -  Known history of active TB (Bacillus Tuberculosis)&#xD;
&#xD;
          -  Hypersensitivity to pembrolizumab or any of its excipients.&#xD;
&#xD;
          -  Known additional malignancies (exceptions DCIS or LCIS, basal cell carcinoma of the&#xD;
             skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has&#xD;
             undergone potentially curative therapy).&#xD;
&#xD;
          -  Prior anti-cancer monoclonal antibody (mAb) within 3 weeks prior to study Day 1 or who&#xD;
             has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents&#xD;
             administered more than 3 weeks earlier.&#xD;
&#xD;
          -  Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2&#xD;
             weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline)&#xD;
             from adverse events due to a previously administered agent.&#xD;
&#xD;
          -  Known carcinomatous meningitis.&#xD;
&#xD;
          -  Active autoimmune disease that has required systemic treatment in the past 2 years.&#xD;
             Patients may be eligible if they have the following autoimmune diseases: thyroiditis&#xD;
             or hypothyroidism, mild arthritis, diabetes, resolved hypophysitis, ulcerative colitis&#xD;
             after total abdominal colectomy.&#xD;
&#xD;
          -  Active infection requiring systemic therapy.&#xD;
&#xD;
          -  Known psychiatric or substance abuse disorders.&#xD;
&#xD;
          -  Known history of Human Immunodeficiency Virus (HIV).&#xD;
&#xD;
          -  Known active Hepatitis B virus (HBV) or Hepatitis C virus (HCV).&#xD;
&#xD;
          -  Has received a live vaccine within 30 days of planned start of study therapy.&#xD;
&#xD;
          -  Severe chronic pulmonary disease.&#xD;
&#xD;
          -  Congestive heart failure, angina, or symptomatic cardiac arrhythmia or is classified&#xD;
             according to the New York Heart Association classification as having Class III or IV&#xD;
             heart disease.&#xD;
&#xD;
          -  History of (non-infectious) pneumonitis that required steroids or current pneumonitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William W Grosh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 23, 2017</study_first_submitted>
  <study_first_submitted_qc>April 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>July 9, 2019</last_update_submitted>
  <last_update_submitted_qc>July 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>William Grosh, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>pembrolizumab</keyword>
  <keyword>IL-2</keyword>
  <keyword>interleukin-2</keyword>
  <keyword>MK-3475</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

